8-K: Phio Pharmaceuticals Advances PH-762, Secures Funding

Phio Pharmaceuticals reports favorable Phase 1b data for lead cancer drug PH-762 and secures $23.7 million, extending cash runway into 2027.

Summary

• Phio Pharmaceuticals Corp. reported its financial results for the year ended December 31, 2025, and provided a business update.
• The Phase 1b dose-escalation clinical trial for PH-762, targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, is complete with favorable safety, tolerability, and pathology data.
• The PH-762 study was fully enrolled in November 2025 with 22 patients.
• An FDA submission is targeted for the second quarter of 2026 to propose and seek guidance for next steps in PH-762 clinical study design.
• The company entered into agreements in 2025 for cGMP manufacturing and a non-clinical toxicology study for PH-762, both required for future pivotal clinical development.
• Phio strengthened its balance sheet in 2025 through equity financings and warrant exercises, generating approximately $23.7 million in net proceeds.
• These financings extended the company's cash runway into the first half of 2027.
• The patent portfolio includes 54 issued patents (49 covering the INTASYL platform) and 20 pending applications, with potential expiration dates between 2029 and 2038.
• Cash and cash equivalents were approximately $21.0 million at December 31, 2025, compared to $5.4 million at December 31, 2024.
• Research and development expenses increased 27% to $4.618 million in 2025, primarily due to the advancement of the PH-762 program and toxicology study planning.
• General and administrative expenses increased 23% to $4.602 million in 2025, driven by higher outsourced professional services and stock-based compensation.
• Net loss for 2025 was approximately $8.7 million, or ($1.45) per share, compared to a net loss of $7.2 million, or ($9.08) per share, in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, driven by successful clinical trial progression for PH-762 and a substantial capital raise that significantly extends the company's financial runway, crucial for continued development.

Positives

• Completion of the Phase 1b dose-escalation trial for PH-762 with favorable safety, tolerability, and pathology data, a significant de-risking event for the lead clinical candidate.
• Successful capital sourcing in 2025 generated approximately $23.7 million in net proceeds, substantially strengthening the balance sheet.
• Cash runway extended into the first half of 2027, providing critical funding for ongoing operations and clinical development.
• Advancement of key manufacturing (cGMP) and toxicology initiatives for PH-762, paving the way for future pivotal clinical trials.
• Robust patent portfolio with 54 issued patents and 20 pending applications, protecting the proprietary INTASYL platform and therapeutic compounds.

Negatives

• Net loss increased to approximately $8.7 million in 2025 from $7.2 million in 2024, indicating continued operational losses.
• Research and development expenses increased by 27% and general and administrative expenses increased by 23% year-over-year, contributing to the higher net loss.

Risks

• The impact of inflationary pressures, rising interest rates, and recession fears on business and operations.
• Uncertainties regarding the development of product candidates and the results from preclinical and clinical activities.
• The ability to execute on business strategies and develop product candidates with collaboration partners, and the success of any such collaborations.
• The timeline and duration for advancing product candidates into clinical development, and the timing or likelihood of regulatory filings and approvals.
• The success of efforts to commercialize product candidates if approved, and the ability to manufacture and supply product candidates for clinical and commercial use.
• The scope of protection the company is able to establish and maintain for intellectual property rights covering its technology platform.
• The ability to obtain future financing to support ongoing operations and development.
• General market and other conditions, and risks identified in the company's Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Phio Pharmaceuticals targets an FDA submission in the second quarter of 2026 to seek guidance for the next clinical study design for PH-762. The company expects its current capital to support ongoing clinical development, operational requirements, and strategic initiatives, extending its cash runway into the first half of 2027. Future pivotal clinical development of PH-762 is planned, supported by cGMP manufacturing and non-clinical toxicology studies.

Management Comments

• Robert Bitterman, President and CEO, stated: "Concluding the Phase 1b study with favorable safety, tolerability and pathology data, advancing the CMC and toxicology initiatives while extending our cash runway into 2027 are noteworthy milestones on our continuing pathway to potential approval."

Industry Context

StockSavvy.ai notes that Phio Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically targeting oncology with siRNA gene silencing technology. The completion of a Phase 1b trial with favorable safety data for PH-762 is a critical de-risking step for a clinical-stage company, aligning with industry trends towards targeted therapies and immunotherapies for cancer. The significant capital raise and extension of cash runway are crucial for continued development in an industry where long development cycles and high R&D costs are standard.

Comparison to Industry Standards

• The completion of a Phase 1b dose-escalation trial with favorable safety and tolerability data for an oncology candidate like PH-762 is a standard and expected milestone in drug development. This initial safety profile is crucial for advancing to larger, later-stage trials.
• While specific comparative efficacy data to other siRNA or PD-1 targeting therapies at this early stage is not provided, favorable safety is a key hurdle. Companies like Alnylam Pharmaceuticals, a pioneer in RNAi therapeutics, or Arrowhead Pharmaceuticals have demonstrated the potential of RNAi technology, setting a high bar for efficacy and safety in later stages.
• The extension of the cash runway into the first half of 2027 is a positive development, as many small biotechs face constant financing challenges. This provides Phio with a more stable financial position compared to peers with shorter cash horizons, allowing for focused development without immediate capital concerns.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress and extended cash runway, potentially increasing long-term value, though dilution from recent financings is noted.
• Employees: Increased job security and stability due to the extended cash runway and continued advancement of development programs.
• Customers (future patients): Potential for a new, non-surgical treatment option for various skin cancers (PH-762) if clinical development continues successfully.
• Suppliers/Partners: Continued engagement and business opportunities with manufacturers and laboratories for CMC and toxicology studies.
• Creditors: Improved financial stability and reduced short-term risk due to a significantly increased cash position.

Next Steps

• Targeted FDA submission in the second quarter of 2026 to propose and seek guidance for next steps in clinical study design for PH-762.
• Continued support for ongoing clinical development, operational requirements, and strategic initiatives with current capital.
• Advancement of PH-762 towards future pivotal clinical development, supported by cGMP manufacturing and non-clinical toxicology studies.

Key Dates

Recommendation

While the completion of the Phase 1b trial with favorable safety data and the significant capital raise are strong positives, Phio Pharmaceuticals remains a clinical-stage company with a lead candidate still in early development. The increased net loss and R&D expenses are typical for this stage but highlight the ongoing cash burn. The extended cash runway provides crucial time, but future financing will likely be needed for pivotal trials. A 'Hold' recommendation reflects the positive momentum balanced against the inherent high risks and long timelines associated with biopharmaceutical development.

Keywords

Phio Pharmaceuticals, PHIO, siRNA, INTASYL, gene silencing, cancer therapeutics, immuno-oncology, PH-762, cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma, clinical trial, Phase 1b, biopharmaceutical, financial results, cash runway, patent portfolio, FDA submission, toxicology study, cGMP manufacturing